About Boehringer Ingelheim

Boehringer Ingelheim develops breakthrough medicines and vaccines for both human and animal health. The company focuses on areas with high unmet medical needs, including oncology, respiratory diseases, metabolic conditions, and infectious diseases across species. With deep expertise in research and development, the company brings scientific innovations from discovery through to global delivery. Founded in 1885 and still family owned, Boehringer Ingelheim operates across more than 130 markets with 54,300 colleagues worldwide. The business invests heavily in long-term research, dedicating over 22% of revenue to R&D. This independence allows the company to prioritise patient and animal outcomes over short term pressures.